Target intelligence / Profile preview

Wiskott-Aldrich syndrome protein family member 3 (WASF3)

Target
WASF3
Molecular classification
Actin-binding protein, Cytoskeleton-associated protein, SCAR/WAVE family, Downstream effector molecule of receptor tyrosine kinases and small GTPases
01

Overview

Wiskott-Aldrich syndrome protein family member 3 (WASF3) is a cytoskeletal regulatory protein belonging to the SCAR/WAVE family, which acts as a key organizer of actin cytoskeleton rearrangement. It links extracellular receptor kinase signals to actin through a multiprotein complex, localizing to the leading edge of motile cells and facilitating lamellipodia formation necessary for cell migration. WASF3 is specifically involved in transmitting signals from tyrosine kinase receptors and small GTPases (such as those activated by PDGF and cytokines), and interacts with the Arp2/3 complex to mediate actin polymerization. Its overexpression is strongly associated with increased cancer cell invasion, epithelial–mesenchymal transition, and metastasis in multiple tumor types. WASF3 is under tight regulatory control by upstream signaling molecules (e.g., PI3K, c-Abl), microRNAs, and protein-protein interactions. Disrupting WASF3 or its regulatory complex is being explored as a strategy for suppressing cancer metastasis

Other names
WAVE3SCAR3BRUSH-1KIAA0900Actin-binding protein WASF3Protein WAVE-3Verprolin homology domain-containing protein 3WASP family Verprolin-homologous protein 3Brush-1
02

Mechanism of action

Inhibition of WASF3 function (experimental) reduces cell motility and metastasis, typically by impairing actin cytoskeleton dynamics

03

Biological functions

Regulation of actin cytoskeletonCell shape and morphology controlCell motility/migration (including lamellipodia formation)Signal transduction linking receptor kinases to actin polymerization
04

Disease associations

Cancer (pro-metastatic regulator in breast, gastric, pancreatic, prostate, esophageal, colorectal, hepatocellular, and cholangiocarcinomas)Wiskott-Aldrich syndromeGanglioneuroblastoma
05

Safety considerations

Targeting cytoskeletal regulators may disrupt normal cell motility and physiological immune responses
06

Biomarkers

Elevated WASF3 expression as a biomarker for invasive/metastatic potential in several cancers

Beyond the preview

Go deeper on Wiskott-Aldrich syndrome protein family member 3 (WASF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wiskott-Aldrich syndrome protein family member 3 (WASF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call